Media.Player

Novel Insight into Inhibiting IGF1 Signaling

Technology Benefits

Inhibits IGF1 signaling Inhibit IGF1 signaling Prevents IGF1-integrin associations Prevents cell proliferation

Technology Application

Inhibiting IGF1 signaling in a cell Identifying inhibitors of IGF1-integrin binding

Detailed Technology Description

IGF1 has been implicated in several aspects of cancer biology. Levels of IGF1 expression are increased in cancers such as breast, lung, and prostate. IGF1 inhibits apoptosis and confers resistance to chemo- and radiation- therapies. Furthermore, high levels of integrin αvβ3, like IGF1, correlate with cancer growth and progression. Traditionally, it has been thought that IGF1 binds to the IGF receptor type 1 (“IGF-IR”) and that integrin αvβ3 binds to extracellular matrix (“EM”) ligands. Based on this prior assumption, IGF1 and IGF-IR have been targets of cancer therapies. Researchers at the University of California, Davis have discovered a new mechanism for IGF1 signaling. They have found that the interaction between IGF1 and certain integrin molecules is involved in IGF1-mediated signaling. More specifically, integrin αvβ3 has been shown to directly interact with IGF1 and it is this interaction which relates to enhanced cell proliferation and αvβ3’s ability to interact with the EM.

Supplementary Information

Patent Number: US8685403B2
Application Number: US13146907A
Inventor: Takada, Yoshikazu | Saegusa, Jun
Priority Date: 30 Jan 2009
Priority Number: US8685403B2
Application Date: 15 Nov 2011
Publication Date: 1 Apr 2014
IPC Current: A61K003900 | C07K001400
US Class: 4241841 | 4241851 | 5140011 | 5140192 | 5140212 | 530350
Assignee Applicant: The Regents of the University of California
Title: Insulin-like growth factor signaling and integrin
Usefulness: Insulin-like growth factor signaling and integrin
Summary: The methods are useful for: inhibiting IGF signaling in a cell within a patient's body; and identifying an inhibitor of IGF-integrin binding (all claimed). Test details are described but no results given.
Novelty: Inhibiting insulin-like growth factor signaling in a cell, comprises contacting the cell with an inhibitor of insulin-like growth factor-integrin binding e.g. anti-beta-3 monoclonal antibody 7E3

Industry

Biomedical

Sub Category

Medical Composition

Application No.

8685403

Others

Additional Technologies by these Inventors

• Suppression of sPLA2-Integrin Binding for Treating an Inflammatory Condition or Suppressing Cell Proliferation
• Novel Fibroblast Growth Factor 1-Derived Peptides for Therapy and Drug Discovery

Tech ID/UC Case

23512/2008-567-0

Related Cases

2008-567-0

*Abstract

A novel method and composition useful for inhibiting IFG1 based on IGF1 mediated signaling.

*IP Issue Date

Apr 1, 2014

*Principal Investigator

Name: Jun Saegusa

Department:

Name: Yoshikazu Takada

Department:

Country/Region

USA